GB1058340A - Transmissible gastroenteritis vaccines and method of producing the same - Google Patents
Transmissible gastroenteritis vaccines and method of producing the sameInfo
- Publication number
- GB1058340A GB1058340A GB40379/65A GB4037965A GB1058340A GB 1058340 A GB1058340 A GB 1058340A GB 40379/65 A GB40379/65 A GB 40379/65A GB 4037965 A GB4037965 A GB 4037965A GB 1058340 A GB1058340 A GB 1058340A
- Authority
- GB
- United Kingdom
- Prior art keywords
- virus
- vaccine
- sow
- pigs
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 229960005486 vaccine Drugs 0.000 title abstract 7
- 208000005577 Gastroenteritis Diseases 0.000 title abstract 3
- 241000700605 Viruses Species 0.000 abstract 18
- 210000001519 tissue Anatomy 0.000 abstract 10
- 241000282887 Suidae Species 0.000 abstract 6
- 241000282472 Canis lupus familiaris Species 0.000 abstract 4
- 238000011534 incubation Methods 0.000 abstract 4
- 238000004519 manufacturing process Methods 0.000 abstract 4
- 230000000474 nursing effect Effects 0.000 abstract 4
- 239000002245 particle Substances 0.000 abstract 4
- 241000283690 Bos taurus Species 0.000 abstract 2
- 241000282326 Felis catus Species 0.000 abstract 2
- 241000282339 Mustela Species 0.000 abstract 2
- 241001494479 Pecora Species 0.000 abstract 2
- 241000282898 Sus scrofa Species 0.000 abstract 2
- 241000711484 Transmissible gastroenteritis virus Species 0.000 abstract 2
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract 2
- 229940031551 inactivated vaccine Drugs 0.000 abstract 2
- 238000011081 inoculation Methods 0.000 abstract 2
- 210000003292 kidney cell Anatomy 0.000 abstract 2
- 239000008267 milk Substances 0.000 abstract 2
- 210000004080 milk Anatomy 0.000 abstract 2
- 235000013336 milk Nutrition 0.000 abstract 2
- 210000004877 mucosa Anatomy 0.000 abstract 2
- 230000000087 stabilizing effect Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 230000003612 virological effect Effects 0.000 abstract 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
- A61K39/225—Porcine transmissible gastroenteritis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20061—Methods of inactivation or attenuation
- C12N2770/20064—Methods of inactivation or attenuation by serial passage
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
In the production of transmissible gastro-enteritis (T.G.E.) virus vaccine, virulent particles of the virus are inoculated into a first tissue culture, the virus is incubated therein for a period up to 24 hours, preferably for from 6 to 14 hours, the viral particles are removed from the culture and inoculated into one or more further tissue cultures, and the incubation and inoculation into further tissue culture or cultures is repeated one or more times. The virus is obtained from the mucosa of the intestinal tracts of infected pigs. Tissues of swine, sheep, cattle, dogs, ferrets and cats may be employed; however, it is preferred to use dog kidney cells for each tissue culture. The incubation of the virulent virus is carried out at 35 DEG to 38 DEG C. The propagation of the virus may be continued until it is rendered avirulent. An inactivated vaccine may be prepared by combining a virus-containing culture with a stabilizing menstrum and incubating at 25 DEG C. for five days. The vaccine can be stored at a low temperature or freeze-dried. Sows and their nursing pigs can be immunized against transmissible gastro-enteritis virus by injecting the virus vaccine into the pregnant sow six weeks before farrowing, thereby stimulating the production of anti-bodies which protect the sow, and nursing the pigs on the sow thereby protecting them against the virus by way of anti-bodies passed in the milk.ALSO:In the production of transmissible gastroenteritis (T.G.E.) virus vaccine, virulent particles of the virus are inoculated into a first tissue culture, the virus is incubated therein for a period up to 24 hours, preferably for from 6 to 14 hours, the viral particles are removed from the culture and inoculated into one or more further tissue cultures, and the incubation and inoculation into further tissue culture or cultures is repeated one or more times. The virus is obtained from the mucosa of the p intestinal tracts of infected pigs. Tissues of swine, sheep, cattle, dogs, ferrets and cats may be employed; however, it is preferred to use dog kidney cells for each tissue culture. The incubation of the virulent virus is carried out at 35 DEG to 38 DEG C. The propagation of the virus may be continued until it is rendered avirulent. An inactivated vaccine may be prepared by combining a virus-containing culture with a stabilizing menstrum and incubating at 25 DEG C for five days. The vaccine can be stored at a low temperature or freeze-dried. Sows and their nursing pigs can be immunized against transmissible gastroenteritis virus by injecting the virus vaccine into the pregnant sow six weeks before farrowing, thereby stimulating the production of antibodies which protect the sow, and nursing the pigs on the sow thereby protecting them against the virus by way of antibodies passed in the milk.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39839864A | 1964-09-22 | 1964-09-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1058340A true GB1058340A (en) | 1967-02-08 |
Family
ID=23575249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB40379/65A Expired GB1058340A (en) | 1964-09-22 | 1965-09-22 | Transmissible gastroenteritis vaccines and method of producing the same |
Country Status (10)
| Country | Link |
|---|---|
| BE (1) | BE669881A (en) |
| CH (1) | CH466894A (en) |
| DE (1) | DE1253412B (en) |
| DK (1) | DK109407C (en) |
| FR (1) | FR1563628A (en) |
| GB (1) | GB1058340A (en) |
| LU (1) | LU49501A1 (en) |
| NL (1) | NL6512094A (en) |
| NO (1) | NO119491B (en) |
| SE (1) | SE358657B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3519710A (en) * | 1967-08-10 | 1970-07-07 | Edmund P Bass | Direct active modified live virus vaccine immunization against transmissible gastroenteritis in swine piglets at birth |
| EP0310316A3 (en) * | 1987-09-28 | 1990-02-14 | Beecham Inc. | Novel vaccine |
| US5911999A (en) * | 1987-09-28 | 1999-06-15 | Pfizer, Inc. | Vaccine based on TGEV for protection of dogs against canine coronavirus |
| US6074651A (en) * | 1988-09-14 | 2000-06-13 | Pfizer, Inc. | Vaccine based on TGEV for protection of canines against canine coronavirus |
-
1965
- 1965-09-02 CH CH1226365A patent/CH466894A/en unknown
- 1965-09-02 DE DED48111A patent/DE1253412B/en active Pending
- 1965-09-06 SE SE11606/65A patent/SE358657B/xx unknown
- 1965-09-16 NL NL6512094A patent/NL6512094A/xx unknown
- 1965-09-20 LU LU49501A patent/LU49501A1/xx unknown
- 1965-09-21 NO NO159782A patent/NO119491B/no unknown
- 1965-09-21 FR FR1563628D patent/FR1563628A/fr not_active Expired
- 1965-09-21 BE BE669881D patent/BE669881A/xx unknown
- 1965-09-22 GB GB40379/65A patent/GB1058340A/en not_active Expired
- 1965-09-22 DK DK486365AA patent/DK109407C/en active
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3519710A (en) * | 1967-08-10 | 1970-07-07 | Edmund P Bass | Direct active modified live virus vaccine immunization against transmissible gastroenteritis in swine piglets at birth |
| EP0310316A3 (en) * | 1987-09-28 | 1990-02-14 | Beecham Inc. | Novel vaccine |
| US5911999A (en) * | 1987-09-28 | 1999-06-15 | Pfizer, Inc. | Vaccine based on TGEV for protection of dogs against canine coronavirus |
| US6074651A (en) * | 1988-09-14 | 2000-06-13 | Pfizer, Inc. | Vaccine based on TGEV for protection of canines against canine coronavirus |
Also Published As
| Publication number | Publication date |
|---|---|
| NO119491B (en) | 1970-05-25 |
| CH466894A (en) | 1968-12-31 |
| SE358657B (en) | 1973-08-06 |
| FR1563628A (en) | 1969-04-18 |
| LU49501A1 (en) | 1966-03-21 |
| DE1253412B (en) | 1967-11-02 |
| NL6512094A (en) | 1966-03-23 |
| BE669881A (en) | 1966-03-21 |
| DK109407C (en) | 1968-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Pye | Vaccination of sheep with cell culture grown orf virus | |
| US3127318A (en) | Swine treatment | |
| de Baugés et al. | Effect of antibiotic therapy and strain-19 vaccination on the spread of Brucella melitensis within an infected dairy herd | |
| NO159782B (en) | SPRING SYSTEM DEVICE, FIRST AND FIRST ON VEHICLES. | |
| ES373631A1 (en) | Live attenuated marek{40 s disease virus vaccine for poultry | |
| US4320115A (en) | Rabies virus vaccine | |
| GB1058340A (en) | Transmissible gastroenteritis vaccines and method of producing the same | |
| Schipper et al. | Evaluation of inactivated infectious bovine rhinotracheitis vaccines | |
| GB1071922A (en) | Improvements in or relating to vaccines | |
| Owen et al. | Bluetongue in cattle: typing of viruses isolated from cattle exposed to natural infections | |
| Cabasso et al. | A bivalent live virus vaccine against canine distemper (CD) and infectious canine hepatitis (ICH). | |
| US3562387A (en) | Mink virus enteritis vaccine and method for the production thereof | |
| US3585108A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| US3000788A (en) | Propagation of modified infectious canine hepatitis virus in tissue cultures of pig kidney and the preparation of a vaccine therefrom | |
| US3704203A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| JP3043353B2 (en) | vaccine | |
| Caldwel | Beef cattle reproductive herd health | |
| US3725542A (en) | Intramuscular vaccination program and vaccine against rhinopneumonitis and process for preparing it | |
| RU2194530C1 (en) | Associated vaccine for preventing diseases in furred animals | |
| US3122477A (en) | Hog cholera vaccine and method of making the same | |
| Pipana | Virulence and immunogenicity of cultured Theileria annulata schizonts | |
| Dalsgaard et al. | Saponin adjuvants. VI. The adjuvant activity of quil A in trivalent vaccination of cattle and guinea pigs against foot-and-mouth disease | |
| Haig | Further observations on the growth of Green's distemperoid virus in developing hen eggs | |
| Wallace et al. | Field trials to assess the value of a bivalent killed salmonella vaccine in the control of ovine salmonellosis | |
| RU1459002C (en) | Vaccine and method for preventing infectious hepatitis in carnivorous animals |